FrancophonIA/ELRC3.0 huggingface dataset:
English: Primary composite endpoint of CV death and heart failure hospitalisations*
Slovenian: primarni cilj opazovanja, sestavljen iz kardiovaskularne smrti in hospitalizacije zaradi srčnega popuščanja*
English: • if you are being treated with an angiotensin receptor blocker (ARB) or aliskiren (see “Do not take Neparvis”).
Slovenian: • če se zdravite z zaviralcem angiotenzinskih receptorjev ali z aliskirenom (glejte pod naslovom
English: Hypotension is the most likely symptom of overdose due to the blood pressure lowering effects of Neparvis.
Slovenian: Glede na to, da zdravilo Neparvis znižuje krvni tlak, bi bil najbolj verjeten simptom prevelikega odmerjanja lahko hipotenzija.
English: ≤ eGFR <60 ml/min/1.73 m 2) and severe renal impairment (15 ml/min/1.73 m eGFR <30 ml/min/1.73 m2) was 1.4-fold and 2.2-fold higher compared to patients with mild renal impairment (60 ml/min/1.73 m
Slovenian: ≤ ocenjena hitrost glomerulne filtracije <60 ml/min/1,73 m 2) in s hudo okvaro ledvic (15 ml/min/1,73 m
English: The primary endpoint was the composite of cardiovascular (CV) death or hospitalisation for heart failure (HF).
Slovenian: Primarni cilj opazovanja je bil sestavljen iz pogostnosti kardiovaskularne smrti in hospitalizacije zaradi srčnega popuščanja.
English: Tabulated list of adverse reactions
Slovenian: Tabelaričen prikaz neželenih učinkov
English: A correlation was observed between renal function and systemic exposure to LBQ657 in patients with mild to severe renal impairment.
Slovenian: Pri bolnikih z blago do hudo okvaro ledvic so opažali korelacijo med ledvično funkcijo in sistemsko izpostavljenostjo substanci LBQ657.
English: • Known history of angioedema related to previous ACE inhibitor or ARB therapy (see section 4.4).
Slovenian: • Anamneza angioedema zaradi predhodnega zdravljenja z zaviralcem ACE ali zaviralcem angiotenzinskih receptorjev (glejte poglavje 4.4).
English: No evidence of embryo-foetal toxicity or teratogenicity was observed in rats treated with sacubitril.
Slovenian: Pri podganah, ki so jim dajali sakubitril, niso opažali nobenih znakov toksičnega delovanje na zarodek oziroma plod ali teratogenosti.
English: Addition of a single dose of sildenafil to Neparvis at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of Neparvis alone.
Slovenian: Zaviralci fosfodiesteraze tipa 5 (PDE5), vključno s sildenafilom Pri bolnikih, ki so imeli hipertenzijo in so dosegli stanje dinamičnega ravnovesja pri odmerjanju zdravila Neparvis, je dodatek enkratnega odmerka sildenafila povzročil bistveno večje znižanje krvnega tlaka kot odmerjanje samo zdravila Neparvis.
English: Neparvis contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).
Slovenian: Interakcije, zaradi katerih sočasna uporaba ni priporočena Zdravilo Neparvis vsebuje valsartan, zato se ga ne sme odmerjati sočasno z drugim zdravilom, ki vsebuje zaviralec angiotenzinskih receptorjev (glejte poglavje 4.4).
English: The combination of Neparvis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see sections 4.3 and 4.5).
Slovenian: Kombinacija zdravila Neparvis z zdravili, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo in pri bolnikih z okvaro ledvic (z ocenjeno hitrostjo glomerulne filtracije <60 ml/min/1,73 m2) (glejte poglavji 4.3 in 4.5).
English: Pale yellow ovaloid biconvex film-coated tablet with bevelled edges, unscored, debossed with “NVR” on one side and “L1” on the other side.
Slovenian: Bledo rumena ovalna bikonveksna filmsko obložena tableta z zaobljenimi robovi, brez razdelilne zareze in z vtisnjenima oznakama "NVR" na eni strani in "L1" na drugi.
English: A starting dose of 24 mg/26 mg twice daily should be considered for patients with SBP ≥100 to 110 mmHg.
Slovenian: Pri bolnikih s sistoličnim krvnim tlakom 100 do 110 mmHg velja razmisliti o začetnem odmerku 24 mg/26 mg dvakrat na dan.
English: The average daily dose of furosemide was unchanged from baseline until the end of the PARADIGM-HF study in patients treated with Neparvis.
Slovenian: V študiji PARADIGM-HF so bolniki, ki so prejemali zdravilo Neparvis, prejemali furosemid v nespremenjenem dnevnem odmerku od izhodišča do konca študije.
English: Very common
Slovenian: pogosti
English: No dose adjustment is required when administering Neparvis to patients with mild hepatic impairment (Child-Pugh A classification).
Slovenian: Pri odmerjanju zdravila Neparvis bolnikom z blago okvaro jeter (Child-Pugh stopnje A) prilagajanje odmerkov ni potrebno.
English: Light pink ovaloid biconvex film-coated tablet with bevelled edges, unscored, debossed with “NVR” on one side and “L11” on the other side.
Slovenian: Svetlo rožnata ovalna bikonveksna filmsko obložena tableta z zaobljenimi robovi, brez razdelilne zareze in z vtisnjenima oznakama "NVR" na eni strani in "L11" na drugi.
English: Down-titration should be considered in patients who develop a clinically significant decrease in renal function.
Slovenian: Pri bolnikih s klinično pomembnim zmanjšanjem delovanja ledvic je treba razmisliti o znižanju odmerjanja zdravila.
English: Neparvis 97 mg/103 mg tablets sacubitril/valsartan
Slovenian: Neparvis 97 mg/103 mg tablete sakubitril/valsartan
English: Neparvis 49 mg/51 mg tablets sacubitril/valsartan
Slovenian: Neparvis 49 mg/51 mg tablete sakubitril/valsartan
English: The concomitant use of Neparvis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see section 4.3).
Slovenian: Sočasna uporaba zdravila Neparvis z zdravili, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo in pri bolnikih z okvaro ledvic (z ocenjeno hitrostjo glomerulne filtracije <60 ml/min/1,73 m2) (glejte poglavje 4.3).
English: Neparvis 24 mg/26 mg tablets sacubitril/valsartan
Slovenian: Neparvis 24mg/26 mg tablete sakubitril/valsartan
English: Unless continued ARB therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Slovenian: Pri bolnicah, ki načrtujejo nosečnost, je treba preiti na uporabo drugih antihipertenzivnih zdravil z uveljavljenim varnostnim profilom za uporabo v nosečnosti; razen, če velja, da je nadaljnje zdravljenje z zaviralcem receptorjev angiotenzina II nujno.
English: Immune system disorders
Slovenian: Bolezni imunskega sistema preobčutljivost občasni
English: Neparvis 24 mg/26 mg film-coated tablets sacubitril/valsartan
Slovenian: Neparvis 24 mg/26 mg filmsko obložene tablete sakubitril/valsartan
English: Impaired renal function
Slovenian: Moteno delovanje ledvic
English: BNP is not a suitable biomarker of heart failure in patients treated with Neparvis because it is a neprilysin substrate (see section 5.1).
Slovenian: Natriuretični peptid tipa B (možganski natriuretični peptid, BNP) Pri bolnikih, ki prejemajo zdravilo Neparvis, možganski natriuretični peptid ni primeren biološki označevalec srčnega popuščanja, saj je substrat neprilizina (glejte poglavje 5.1).
English: Hepatic impairment
Slovenian: Zdravilo Neparvis
English: Each 49 mg/51 mg tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: Ena 49 mg/51 mg tableta vsebuje 48,6 mg sakubitrila in 51,4 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: Violet white ovaloid biconvex film-coated tablet with bevelled edges, unscored, debossed with “NVR” on one side and “LZ” on the other side.
Slovenian: Vijoličasto bela ovalna bikonveksna filmsko obložena tableta z zaobljenimi robovi, brez razdelilne zareze in z vtisnjenima oznakama "NVR" na eni strani in "LZ" na drugi.
English: Individual components of the primary composite endpoint CV death**
Slovenian: Posamezni dogodki primarnega sestavljenega cilja opazovanja kardiovaskularna smrt** prva hospitalizacija zaradi srčnega popuščanja
English: Angioedema has been reported in patients treated with Neparvis.
Slovenian: Pri bolnikih, ki so prejemali zdravilo Neparvis, so poročali o angioedemu.
English: Neparvis 49 mg/51 mg film-coated tablets sacubitril/valsartan
Slovenian: Neparvis 49 mg/51 mg filmsko obložene tablete sakubitril/valsartan
English: Neparvis 97 mg/103 mg film-coated tablets sacubitril/valsartan
Slovenian: Neparvis 97 mg/103 mg filmsko obložene tablete sakubitril/valsartan
English: Monitoring of serum potassium is recommended if Neparvis is co-administered with these agents (see section 4.4).
Slovenian: Pri sočasni uporabi zdravila Neparvis in navedenih zdravil je priporočeno spremljanje vrednosti kalija v serumu (glejte poglavje 4.4).
English: How to store Neparvis
Slovenian: Shranjevanje zdravila Neparvis
English: • spinning sensation
Slovenian: • izguba zavesti
English: Neparvis may therefore increase the systemic exposure of OATP1B1 and OATP1B3 substrates such as statins.
Slovenian: Substrati prenašalcev OATP1B1 in OATP1B3, na primer statini Podatki in vitro kažejo, da sakubitril zavira prenašalca OATP1B1 in OATP1B3, zato bi zdravilo Neparvis lahko povečalo sistemsko izpostavljenost substratom OATP1B1 in OATP1B3, kot so statini.
English: Neparvis must not be started until 36 hours after taking the last dose of ACE inhibitor therapy.
Slovenian: Zdravljenja z zdravilom Neparvis se ne sme začeti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zaviralca ACE.
English: A slight generalised delay in ossification was observed at doses of >50 mg/kg/day.
Slovenian: Pri odmerkih >50 mg/kg/dan so opažali blago generalizirano zakasnitev zakostenevanja.
English: Each film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: Ena filmsko obložena tableta vsebuje 48,6 mg sakubitrila in 51,4 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: Neparvis must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
Slovenian: Zdravila Neparvis se ne sme odmerjati prej kot po preteku 36 ur od prekinitve zdravljenja z zaviralcem ACE.
English: Cough
Slovenian: Kalij
English: • high level of potassium in the blood (shown in a blood test)
Slovenian: • visoka raven kalija v krvi (kar pokaže izvid krvne preiskave)
English: o Each 49 mg/51 mg film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: o Ena 49 mg/51 mg filmsko obložena tableta vsebuje 48,6 mg sakubitrila in 51,4 mg valsartana v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: Neparvis must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy.
Slovenian: Zdravljenja z zdravilom Neparvis se ne sme uvesti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zaviralca ACE.
English: You must tell your doctor if you think that you are (or might become) pregnant.
Slovenian: Zdravniku morate povedati, če mislite, da ste noseči ali da bi lahko zanosili.
English: Metabolism and nutrition disorders
Slovenian: Presnovne in prehranske motnje hiperkaliemija*
English: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors or angiotensin II receptor antagonists.
Slovenian: Zdravila Neparvis se ne sme odmerjati sočasno z zaviralcem ACE ali zaviralcem receptorjev angiotenzina II.
English: Neparvis 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Slovenian: Neparvis 97 mg/103 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) črni železov oksid (E172)
English: Neparvis 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Slovenian: Neparvis 49 mg/51 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) rumeni železov oksid (E172)
English: Each film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: Ena filmsko obložena tableta vsebuje 97,2 mg sakubitrila in 102,8 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: Neparvis 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Slovenian: Neparvis 24 mg/26 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) črni železov oksid (E172)
English: Each 24 mg/26 mg tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: Ena 24 mg/26 mg tableta vsebuje 24,3 mg sakubitrila in 25,7 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: Therefore, co-administration of Neparvis with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir,
Slovenian: Iz tega razloga lahko sočasna uporaba zdravila Neparvis z zaviralci OATP1B1, OATP1B3, OAT3 (kot sta rifampicin in ciklosporin), OAT1 (kot sta tenofovir in cidofovir) ali MRP2 (kot je ritonavir) poveča sistemsko izpostavljenost substanci LBQ657 oziroma valsartanu.
English: Each 97 mg/103 mg tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: Ena 97 mg/103 mg tableta vsebuje 97,2 mg sakubitrila in 102,8 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: • low level of potassium in the blood (shown in a blood test)
Slovenian: • nizka raven kalija v krvi (kar pokaže izvid krvne preiskave)
English: Losartan 150
Slovenian: Roonstrasse 25
English: o Each 24 mg/26 mg film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: o Ena 24 mg/26 mg filmsko obložena tableta vsebuje 24,3 mg sakubitrila in 25,7 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: Each film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: Ena filmsko obložena tableta vsebuje 24,3 mg sakubitrila in 25,7 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: Neparvis 49 mg/51 mg film-coated tablets are pale yellow oval tablets with “NVR” on one side and “L1” on the other side.
Slovenian: Tablete so velike približno 13,1 mm x 5,2 mm. Neparvis 49 mg/51 mg filmsko obložene tablete so bledo rumene ovalne tablete z vtisnjenima oznakama "NVR" na eni strani in "L1" na drugi.
English: o Each 97 mg/103 mg film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Slovenian: o Ena 97 mg/103 mg filmsko obložena tableta vsebuje 97,2 mg sakubitrila in 102,8 mg valsartana v obliki kompleksa natrijeve soli sakubitrila in valsartana).
English: A starting dose of 24 mg/26 mg twice daily should be considered in patients with moderate renal impairment (eGFR 30-60 ml/min/1.73 m2).
Slovenian: 1,4-krat oziroma 2,2-krat večja kot pri bolnikih z blago okvaro ledvic (60 ml/min/1,73 m
English: Gastrointestinal disorders
Slovenian: Študija TITRATION
English: A similar effect on the heart rate may occur when Neparvis is co-administered with sublingual, oral or transdermal nitrates.
Slovenian: Pri sočasni uporabi zdravila Neparvis in sublingvalne, peroralne ali transdermalne oblike nitratov lahko pride do podobnih učinkov na srčno frekvenco.
English: Renal impairment*
Slovenian: Bolezni sečil okvara ledvic*
English: Your doctor may check the amount of potassium in your blood at regular intervals during Neparvis treatment.
Slovenian: V času zdravljenja z zdravilom Neparvis vam bo zdravnik verjetno redno preverjal koncentracijo kalija v krvi.
English: • dizziness
Slovenian: • vrtoglavica
English: Do not take Neparvis with ACE inhibitors.
Slovenian: • zaviralcev ACE: zdravila Neparvis ne smete jemati sočasno z zaviralci ACE.
English: All-cause mortality 711 (16.98) 835 (19.82) 0.84 (0.76, 0.93) 16% 0.0005 *The primary endpoint was defined as the time to first event of CV death or hospitalisation for HF. **CV death includes all patients who died up to the cut-off date irrespective of previous hospitalisation.
Slovenian: Sekundarni cilj opazovanja umrljivost iz kateregakoli vzroka * primarni cilj opazovanja je bil opredeljen kot čas do prvega od dveh dogodkov: kardiovaskularne smrti ali hospitalizacije zaradi srčnega popuščanja ** kardiovaskularna smrt vključuje vse bolnike, ki so umrli do vnaprej določenega datuma ne glede na predhodne hospitalizacije *** vrednost p za enostranski test skupina bolnikov za celotno analizo (angl. full analysis set)
English: Fatigue
Slovenian: • utrujenost
English: Impaired hepatic function
Slovenian: Žilne bolezni hipotenzija*
English: This overview was last updated in 03-2019.
Slovenian: Povzetek je bil nazadnje posodobljen 03-2019.
English: Further information on Revolade can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Revolade.
Slovenian: Nadaljnje informacije o zdravilu Revolade so na voljo na spletni strani agencije:ema.europa.eu/medicines/human/EPAR/Revolade.
English: Revolade received a marketing authorisation valid throughout the EU on 11 March 2010.
Slovenian: Za zdravilo Revolade je bilo 11. marca 2010 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
English: What measures are being taken to ensure the safe and effective use of Revolade?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Revolade?
English: Revolade is a medicine that is used for the treatment of:
Slovenian: Revolade je zdravilo, ki se uporablja za zdravljenje:
English: The European Medicines Agency decided that Revolade's benefits are greater than its risks and recommended that it be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Revolade večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Other information about Revolade
Slovenian: Druge informacije o zdravilu Revolade
English: As for all medicines, data on the use of Revolade are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Revolade stalno spremljajo.
English: What benefits of Revolade have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Revolade izkazalo v študijah?
English: An extension of the study found that Revolade was effective at maintaining adequate levels of platelets in the long term.
Slovenian: V podaljšanju študije so ugotovili, da je bilo zdravilo Revolade učinkovito tudi za dolgoročno ohranjanje ustreznih ravni trombocitov.
English: Severe aplastic anaemia
Slovenian: Huda aplastična anemija
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Revolade have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Revolade upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: An overview of Revolade and why it is authorised in the EU
Slovenian: Pregled zdravila Revolade in zakaj je odobreno v EU
English: Preliminary data from a supportive study are consistent with the result of the main study, with 46% of patients responding to treatment after 12 weeks.
Slovenian: Predhodni rezultati podporne študije se ujemajo z rezultati glavne študije, saj se je po 12 tednih na zdravljenje odzvalo 46 % bolnikov.
English: For the treatment of thrombocytopenia associated with hepatitis C, two main studies involving a total of 1,441 adults were carried out.
Slovenian: V zvezi z zdravljenjem trombocitopenije, povezane s hepatitisom C, sta bili izvedeni dve glavni študiji, v katerih je sodelovalo skupno 1 441 odraslih.
English: The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in treating blood diseases or chronic hepatitis C and its complications.
Slovenian: Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem krvnih obolenj ali kroničnega hepatitisa C in z njim povezanih zapletov.
English: Why is Revolade authorised in the EU?
Slovenian: Zakaj je zdravilo Revolade odobreno v EU?
English: What are the risks associated with Revolade?
Slovenian: Kakšna tveganja so povezana z zdravilom Revolade?
English: Revolade is available as tablets (12.5, 25, 50 and 75 mg) and as a powder (25 mg) to prepare a suspension (a liquid) to be taken by mouth.
Slovenian: Zdravilo Revolade je na voljo v obliki tablet (12,5 mg, 25 mg, 50 mg in 75 mg) in praška (25 mg) za pripravo suspenzije (tekočine) za peroralno uporabo.
English: For the treatment of severe aplastic anaemia, Revolade was studied in 43 patients and it was not compared with any other medicine.
Slovenian: V zvezi z zdravljenjem hude aplastične anemije so uporabo zdravila Revolade proučevali pri 43 bolnikih in ga niso primerjali z nobenim drugim zdravilom.
English: What is Revolade and what is it used for?
Slovenian: Kaj je zdravilo Revolade in za kaj se uporablja?
English: For more information about using Revolade, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Revolade glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Side effects reported with Revolade are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Revolade, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Revolade is used in patients from 1 year of age who have had the disease for at least 6 months and for whom treatment with medicines such as corticosteroids or immunoglobulins has not worked;
Slovenian: Zdravilo Revolade se uporablja pri bolnikih od enega leta dalje, ki so bolni najmanj šest mesecev in pri katerih zdravljenje z zdravili, kot so kortikosteroidi ali imunoglobulini, ni delovalo;
English: For ITP and aplastic anaemia, a lower starting dose should be used in patients of Asian descent (such as Chinese, Japanese, Korean or Taiwanese people).
Slovenian: Pri imunski trombocitopenični purpuri in aplastični anemiji je treba pri bolnikih azijskega porekla (kot so Kitajci, Japonci, Korejci ali Tajvanci) uporabiti manjši začetni odmerek.
English: In both studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 6 months after the end of treatment.
Slovenian: Glavno merilo učinkovitosti v obeh študijah je bilo število bolnikov, pri katerih krvne preiskave šest mesecev po zaključku zdravljenja niso pokazale nobenih znakov prisotnosti virusa hepatitisa C.
English: Thrombocytopenia associated with hepatitis C
Slovenian: Trombocitopenija, povezana s hepatitisom C
English: Revolade is used in adult patients whose disease is not controlled by immunosuppressive therapy (medicines that lower the body's immune defences) and cannot receive haematopoietic stem cell transplantation (where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow).
Slovenian: Zdravilo Revolade se uporablja pri odraslih, katerih bolezen ni nadzorovana z imunosupresivno terapijo (zdravili, ki znižujejo imunsko obrambo telesa) in pri katerih ni mogoče opraviti presaditve hematopoetskih matičnih celic (kadar se bolnikov kostni mozeg nadomesti z izvornimi celicami darovalca, ki tvorijo nov kostni mozeg).